Mission Statement, Vision, & Core Values (2026) of Yunnan Botanee Bio-Technology Group Co.LTD.

Founded in 2010, Yunnan Botanee Bio-Technology Group Co., Ltd. (listed on ChiNext in 2021, stock code 300957) has positioned its Winona brand and R&D-driven platform at the intersection of dermatology-grade functional skincare and digital health, pursuing a mission to 'create China's skin health ecosystem' by commercializing Yunnan plateau botanicals under GMPC standards and building international R&D links in Japan and Switzerland; the company's vision to 'bring health and beauty to everyone' is backed by concrete targets - expanding exports to over 40 countries with a projected 25% uplift in international sales, achieving ISO 9001 certification in 2023, cutting CO2 emissions by 30% through production improvements, and raising a customer satisfaction score already at 92% toward 95% - while core values of integrity, result-orientation, simplicity, and employee empowerment drive OMO retail integration, AI-enabled operations (AI live streaming, AI content and service, AI advertising), and the industrialization of high-barrier functional health products spanning cosmetics, functional foods, and potential Class II/III medical applications.

Yunnan Botanee Bio-Technology Group Co.LTD (300957.SZ) - Intro

• Founded in 2010, Yunnan Botanee Bio-Technology Group Co.LTD (300957.SZ) is a leading Chinese 'big health' enterprise focused on R&D, production and marketing of dermatologically oriented skincare, with a core specialization in formulations for sensitive skin.
• Flagship brand: Winona - positioned as dermatological-grade, hypoallergenic skincare built on patented technologies and GMPC-compliant production suitable for US/EU market expectations.
• Listed on Shenzhen ChiNext in 2021 (stock code 300957), recognized as the largest listed company in China focusing on functional skincare for sensitive skin.

• To safeguard skin health for sensitive populations through evidence-based, science-driven skincare derived from Yunnan plateau botanical resources.
• To integrate clinical dermatology, modern biotechnology and safe manufacturing to deliver gentle, effective products accessible across digital and offline channels.

• Become a global leader in functional, dermatology-backed skincare by 2030, leveraging patented actives from Yunnan biodiversity and AI-enabled personalization.
• Expand Winona and complementary brands into broader international markets while maintaining high safety and clinical efficacy standards.

• Safety-first: strict adherence to GMPC and clinical validation for sensitive skin formulations.
• Science-driven innovation: sustained investment in R&D, clinical trials and patented actives.
• Integrity & transparency: regulatory compliance, traceability of botanical sources and clear consumer communication.
• Omni-channel accessibility: seamless consumer experience across online, offline and OMO (online-merge-offline) distribution.

• R&D integration - industry, academia, research institutions and clinical partners to identify active ingredients endemic to the Yunnan plateau.
• Product quality - manufacturing under GMPC, dermatological testing and patented gentle formulas for sensitive skin needs.
• Digital transformation - 'Internet Plus' skin health strategy: AI-driven user profiling, personalized regimens, and data-supported marketing.
• Retail & OMO - an expanding touchpoint network combining e-commerce, specialty stores, pharmacy channels and cross-industry partnerships.

• Center integrates cross-disciplinary teams targeting: anti-inflammatory actives, barrier-repair technologies, microbiome-friendly formulations and low-irritant preservative systems.
• Pipeline emphasis on leveraging unique plateau plant actives (patent portfolio growth since 2018) and clinical evidence generation for product claims.

• Manufacturing: multiple GMP/GMPC-compliant facilities with quality control systems aligned to export requirements.
• Sales channels: direct e-commerce (brand flagship stores and major marketplaces), pharmacy/OTC distribution, specialty skin clinics and cross-industry partnerships enabled by OMO strategies.
• Marketing: dermatologist endorsements, clinical data communication, influencer and community education to reach sensitive-skin consumers.

• Botanee emphasizes sustainable sourcing of botanical raw materials from the Yunnan plateau with traceability programs and agricultural partner support.
• Quality, safety and environmental controls at manufacturing sites to meet export standards and reduce ecological footprint.

• Regulatory and safety risk - mitigated by adherence to GMPC and clinical validation for sensitive-skin claims.
• Competitive pressure from domestic and international functional skincare brands - mitigated through patent protection, dermatologist partnerships and OMO retail expansion.
• Supply-chain concentration for plateau botanicals - mitigated via cooperative farming programs and diversification of sourcing bases.

• Transparent financial reporting since ChiNext listing; ongoing investor outreach emphasizing R&D pipeline, margin improvements and OMO scaling.
• Accessible investor profile and updates: Exploring Yunnan Botanee Bio-Technology Group Co.LTD Investor Profile: Who's Buying and Why?

Yunnan Botanee Bio-Technology Group Co.LTD (300957.SZ) - Overview

• Create China's skin health ecosystem by providing professional skincare and makeup products tailored to diverse skin needs.
• Build a dermatological health ecosystem by integrating Internet technologies across R&D, channels, and service delivery.
• Develop functional cosmetics (soothing, spot lightening, barrier repair, firming, sun protection) and functional foods for soothing, spot lightening, and firming.
• Establish international R&D centers (planned/aggressive focus: Japan and Switzerland) to access cutting‑edge technologies and collaborate on core technology challenges.
• Adopt AI across the business - AI live streaming, AI-generated content, AI customer service, and AI advertising delivery - to raise operational efficiency and precision marketing.
• Advance high-value health products with strong technological barriers and industrialize applications of Yunnan specialty plants into pharmaceuticals, Class II/III medical devices, and other health products.

• Position Yunnan Botanee as the leading Chinese integrator of dermatological science, traditional botanical resources, and digital/AI-enabled delivery systems.
• Transform from a cosmetics-first firm into a skin health platform spanning cosmetics, medical devices, nutraceuticals, and digital health services.
• Be recognized globally for plant-based, clinically validated, and digitally distributed skin-health solutions.

• Science-driven innovation - prioritize R&D, clinical validation, and cross-border scientific collaboration.
• Integrity & safety - rigorous quality control from raw botanical sourcing to finished product and compliance with medical device/pharmaceutical standards where applicable.
• Customer-centricity - personalize solutions for varied skin types and conditions leveraging data and AI insights.
• Sustainability - responsible cultivation and utilization of Yunnan native plant resources and ecological stewardship.
• Open collaboration - partnerships with international research centers and ecosystems to accelerate technology adoption.

• International R&D hubs: targeted Japan and Switzerland centers to access dermatology, formulation, and regulatory expertise.
• R&D focus areas: anti‑inflammation/soothing, pigment regulation/spot lightening, barrier repair, firming, photoprotection, and functional oral supplements.
• AI adoption plan: integrate AI for content generation, live commerce optimization, customer service bots, and programmatic ad delivery to lower CAC and raise conversion rates.
• Industrialization: develop Class II/III device candidates and botanical-derived pharmaceutical leads using Yunnan specialty plants with IP protection and high technical barriers.

• Product portfolio expansion: pipeline includes high-barrier therapeutic cosmetics and nutraceuticals leveraging Yunnan botanicals for clinical indications (e.g., sensitive skin, hyperpigmentation, barrier dysfunction).
• Clinical validation: scale clinical trials and dermatology partnerships to convert cosmetic claims into medical-grade indications where feasible.
• AI & digital commerce scaling: combine AI live streaming and AI content to improve conversion rates, reduce customer acquisition costs, and enhance post‑purchase adherence.
• Regulatory pathway development: pursue Class II/III device registration and pharmaceutical pipelines to upgrade product value and pricing power.

Yunnan Botanee Bio-Technology Group Co.LTD (300957.SZ) - Mission Statement

Yunnan Botanee Bio-Technology Group Co.LTD (300957.SZ) centers its mission on delivering scientifically validated natural health and beauty solutions that enhance quality of life worldwide. Combining botanical resources from Yunnan with advanced biotechnology, the company pursues measurable impact across product efficacy, environmental stewardship, and global accessibility.

• Mission: Develop safe, effective, and sustainable bioactive products that make health and beauty accessible to diverse populations.
• Strategic focus: Integrate R&D, quality management, and international distribution to scale trusted formulations.
• Customer promise: Prioritize safety, transparency, and measurable outcomes to maintain high satisfaction and repeat use.

Vision Statement

Botanee's vision is to 'bring health and beauty to everyone' by integrating advanced technology with natural ingredients. Key quantitative commitments underpinning this vision include:

• R&D investment: Targeting R&D expenditure of 8-10% of annual revenue to accelerate new biotechnological solutions and product formulation improvements.
• Environmental goal: Achieve a 30% reduction in CO2 emissions via process optimization, energy-efficiency upgrades, and green logistics initiatives.
• International expansion: Export footprint in over 40 countries with a projected 25% compound growth in international sales over the next 3 years, with priority markets in the United States and major European countries.
• Quality and regulatory: Maintain ISO 9001 certification (awarded in 2023) and pursue US FDA approvals for specific product lines to support market entry and trust.
• Customer focus: Improve customer satisfaction from 92% (2023) to 95% through enhanced feedback systems and product portfolio refinement.

2023 Performance vs Near-Term Targets

Core Values and Operational Priorities

• Science-led integrity - rigorous evidence and transparent claims supported by clinical and analytical data.
• Sustainability - responsible sourcing of botanicals, reduced carbon intensity, and circular production practices.
• Quality first - ISO 9001 systems, batch traceability, and GMP-aligned manufacturing processes.
• Global accessibility - scalable formulations and regulatory pathways to bring products to 40+ international markets.
• Customer-centric innovation - leveraging customer feedback (92% satisfaction in 2023) to reach 95% via product enhancements and service improvements.

Key Initiatives Driving the Vision

• Scale R&D: Expand research centers and partnerships with universities to reach targeted 8-10% revenue R&D spend; aim to file 12 new patents by 2025.
• Green manufacturing: Retrofit primary production sites to reduce energy use and cut CO2 emissions by 30% from 2023 baseline.
• Regulatory roadmap: Accelerate submissions for US FDA clearances and CE/EMA compliance to unlock priority export markets.
• International distribution: Strengthen distributor network to achieve presence in 40+ countries and 25% growth in international revenue.
• Quality assurance: Maintain ISO 9001 systems and pursue additional certifications aligned with target markets.

For more on the company's financial profile and investor-relevant metrics see: Breaking Down Yunnan Botanee Bio-Technology Group Co.LTD Financial Health: Key Insights for Investors

Yunnan Botanee Bio-Technology Group Co.LTD (300957.SZ) - Vision Statement

• Pursuit of excellence: continuous improvement across R&D, quality control, and production to meet global pharmacopeia and food-grade standards.
• Simplicity and transparency: streamlined processes and clear disclosure practices to boost investor and customer trust.
• Result orientation: KPI-driven operations to translate research into marketable products and revenue growth.
• Diligence and dedication: maintaining high operational discipline in cultivation, extraction and downstream formulation.
• Gratitude and goodwill: building long-term partnerships with suppliers, distributors and local communities.
• Integrity and pragmatism: bottom-line integrity as the baseline for sustainable development and risk management.

• Zero-tolerance stance on corruption, bribery, unfair competition and money laundering; mandatory compliance training for all employees and third-party partners.
• Behavioral norms for management require demonstrable integrity and pragmatic decision-making; escalation channels and whistleblower protections are institutionalized.
• Supplier and customer codes of conduct that extend anti-corruption and ESG expectations across the value chain.

• Frontline empowerment: strategic shift to delegate decision-making to business units supported by a robust middle/back-office system to accelerate market responses.
• Job-ranking management system: clear career ladders, competency frameworks and transparent promotion metrics to retain and motivate employees.
• Compensation and incentives: market-competitive pay, performance bonuses and long-term retention tools to attract talent and instill internal pride.
• Employee-centric culture: workforce development programs, on-site training and wellness programs reflecting the company's view of employees as its most valuable asset.

• Scale-up of GMP-compliant production lines to support global pharmaceutical and nutraceutical contracts.
• Increased investment in standardized cultivation and traceability systems to secure raw material quality and sustainability credentials.
• Expanded partnerships with academic institutions and CROs to accelerate clinical validation and product registration in new markets.